TET2 is altered in 13.92% of acute myeloid leukemia patients with TET2 Loss present in 0.29% of all acute myeloid leukemia patients [4].

TET2 Loss is an inclusion criterion in 6 clinical trials for acute myeloid leukemia, of which 5 are open and 1 is closed. Of the trials that contain TET2 Loss and acute myeloid leukemia as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [5].

TET2 is altered in 19.3% of myelodysplastic syndromes patients with TET2 Loss present in 0.55% of all myelodysplastic syndromes patients [4].

TET2 Loss is an inclusion criterion in 5 clinical trials for myelodysplastic syndromes, of which 3 are open and 2 are closed. Of the trials that contain TET2 Loss and myelodysplastic syndromes as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].

TET2 is altered in 47.59% of chronic myelomonocytic leukemia patients with TET2 Loss present in 1.56% of all chronic myelomonocytic leukemia patients [4].

TET2 Loss is an inclusion criterion in 2 clinical trials for chronic myelomonocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain TET2 Loss and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

TET2 is altered in 9.62% of lymphoma patients with TET2 Loss present in 0.32% of all lymphoma patients [4].

TET2 Loss is an inclusion criterion in 2 clinical trials for lymphoma, of which 1 is open and 1 is closed. Of the trials that contain TET2 Loss and lymphoma as inclusion criteria, 2 are phase 1 (1 open) [5].

TET2 is altered in 3.54% of malignant solid tumor patients with TET2 Loss present in 0.06% of all malignant solid tumor patients [4].

TET2 Loss is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain TET2 Loss and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) [5].

TET2 is altered in 14.29% of acute lymphoblastic leukemia patients [4].

TET2 Loss is an inclusion criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain TET2 Loss and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (2 open) [5].

TET2 is altered in 5.98% of chronic myeloid leukemia patients [4].

TET2 Loss is an inclusion criterion in 2 clinical trials for chronic myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain TET2 Loss and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

TET2 is altered in 37.06% of myelodysplastic/myeloproliferative neoplasm patients with TET2 Loss present in 0.98% of all myelodysplastic/myeloproliferative neoplasm patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TET2 Loss and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

TET2 is altered in 5.04% of anaplastic astrocytoma patients with TET2 Loss present in 0.36% of all anaplastic astrocytoma patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 Loss and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TET2 is altered in 11.18% of non-hodgkin lymphoma patients with TET2 Loss present in 0.34% of all non-hodgkin lymphoma patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TET2 is altered in 3.46% of head and neck carcinoma patients with TET2 Loss present in 0.26% of all head and neck carcinoma patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 Loss and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TET2 is altered in 3.33% of malignant central nervous system neoplasm patients with TET2 Loss present in 0.11% of all malignant central nervous system neoplasm patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

TET2 is altered in 4.64% of bladder carcinoma patients with TET2 Loss present in 0.07% of all bladder carcinoma patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 Loss and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TET2 is altered in 4.31% of colorectal carcinoma patients with TET2 Loss present in 0.07% of all colorectal carcinoma patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 Loss and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TET2 is altered in 3.38% of glioblastoma patients with TET2 Loss present in 0.05% of all glioblastoma patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 Loss and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TET2 is altered in 2.41% of ovarian carcinoma patients with TET2 Loss present in 0.05% of all ovarian carcinoma patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 Loss and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TET2 is altered in 1.97% of pancreatic carcinoma patients with TET2 Loss present in 0.04% of all pancreatic carcinoma patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 Loss and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TET2 is altered in 1.49% of sarcoma patients with TET2 Loss present in 0.03% of all sarcoma patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 Loss and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TET2 is altered in 1.86% of breast carcinoma patients with TET2 Loss present in 0.02% of all breast carcinoma patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 Loss and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TET2 Loss is an inclusion criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

TET2 is altered in 11.86% of acute leukemia of ambiguous lineage patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 1 (1 open) [5].

TET2 Loss is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [5].

TET2 Loss is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

TET2 is altered in 4.74% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TET2 Loss is an inclusion criterion in 1 clinical trial for extrarenal rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and extrarenal rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

TET2 is altered in 7.69% of hepatoblastoma patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and hepatoblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TET2 is altered in 5.36% of hodgkin lymphoma patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TET2 Loss is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TET2 is altered in 10.95% of melanoma patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 Loss and melanoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TET2 is altered in 12.5% of mixed phenotype acute leukemia patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

TET2 is altered in 7.35% of multiple myeloma patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [5].

TET2 is altered in 4.04% of non-small cell lung carcinoma patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 Loss and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TET2 is altered in 2.41% of retinoblastoma patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for retinoblastoma, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and retinoblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TET2 Loss is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

TET2 Loss is an inclusion criterion in 1 clinical trial for rhabdoid tumor of the kidney, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and rhabdoid tumor of the kidney as inclusion criteria, 1 is phase 1 (1 open) [5].

TET2 Loss is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

TET2 is altered in 11.27% of therapy-related myelodysplastic syndrome patients [4].

TET2 Loss is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains TET2 Loss and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [5].